Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Key Points Pfizer and Novo Nordisk have underperformed the market over the past year.But both should remain major players in ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.

The North America Clinical Trials Market is projected to grow from US$ 20.07 billion in 2024 to US$ 33.91 billion by 2033, registering a CAGR of 6.00% from 2025 to 2033. Key drivers include the ...

Bristol Myers Squibb has appointed Dr Cristian Massacesi as Executive Vice President, Chief Medical Officer and Head of ...

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages - including the XFG and NB.1.8.1 variants1 - compared to ...

Pfizer and Astellas Pharma have shared positive top-line results from a late-stage study of their androgen receptor ...